140 related articles for article (PubMed ID: 36797154)
1. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis.
Shank BR; Primeaux B; Yeung EK; Horowitz SB; Lee IY; Roccograndi L; Feng L; Kaufman GP; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Weber DM; Becnel MR; Thomas SK
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):279-290. PubMed ID: 36797154
[TBL] [Abstract][Full Text] [Related]
2. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Pennipede D; Mohyuddin GR; Hawkins R; Ganguly S; Shune L; Ahmed N; Mohan M; Cui W; Mahmoudjafari Z; McGuirk J; Atrash S; Abdallah AO
Eur J Haematol; 2021 Dec; 107(6):602-608. PubMed ID: 34378251
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
8. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
11. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
14. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
[TBL] [Abstract][Full Text] [Related]
15. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM; Efebera YA; Hájek R; Straub J; Maisnar V; Eveillard JR; Karlin L; Mateos MV; Oriol A; Ribrag V; Richardson PG; Norin S; Obermüller J; Bakker NA; Pour L
Haematologica; 2024 Mar; 109(3):867-876. PubMed ID: 37646657
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of weekly carfilzomib 70 mg/m
Puertas B; González-Calle V; Sureda A; Moreno MJ; Oriol A; González E; Rosiñol L; López J; Escalante F; Martínez-Lopez J; Carrillo E; Clavero E; Ríos-Tamayo R; Rey-Bua B; González-Rodríguez AP; Dourdil V; De Arriba F; González S; Pérez-de-Oteyza J; Hernández MT; García-Mateo A; Bargay J; Bladé J; Lahuerta JJ; San Miguel JF; Ocio EM; Mateos MV
Haematologica; 2023 Oct; 108(10):2753-2763. PubMed ID: 37102598
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Hájek R; Masszi T; Petrucci MT; Palumbo A; Rosiñol L; Nagler A; Yong KL; Oriol A; Minarik J; Pour L; Dimopoulos MA; Maisnar V; Rossi D; Kasparu H; Van Droogenbroeck J; Yehuda DB; Hardan I; Jenner M; Calbecka M; Dávid M; de la Rubia J; Drach J; Gasztonyi Z; Górnik S; Leleu X; Munder M; Offidani M; Zojer N; Rajangam K; Chang YL; San-Miguel JF; Ludwig H
Leukemia; 2017 Jan; 31(1):107-114. PubMed ID: 27416912
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L; Szarejko M; Bila J; Schjesvold FH; Spicka I; Maisnar V; Jurczyszyn A; Grudeva-Popova Z; Hájek R; Usenko G; Thuresson M; Norin S; Jarefors S; Bakker NA; Richardson PG; Mateos MV
Haematologica; 2024 Mar; 109(3):895-905. PubMed ID: 37646660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
